Peptides DB
Research-centric peptide and protocol reference hub

CJC-1295 record · updated 17h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 11 studiesJump to the evidenceCompare
What is CJC-1295 used for?

GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.

How it works: GHRH (1–29) analog, modified

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where CJC-1295 sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 38 registered trials. It describes the research record, not a recommendation.

Identity
NameCJC-1295
Chain length—
Molecular weight3,647.2 Da
FormulaC165H269N47O46
Structure typeNot established
ClassMuscle
Research levelLimited Research
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 91971820. No verified residue count for this compound.

Pharmacology
MechanismGHRH (1–29) analog, modified
RouteSubcutaneous injection
Half-life~30 min
Time to peak—
Duration—
Extraction confidence0.60
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 9, 2026. How this works →
Research stats
Total studies11
Human / animal / cellular4 / 0 / 0
Highest trial phasePhase 4
Years covered2010–2026
Latest study28d ago
Publication history
20102026
Research funding
38 NIH projects · $16.8M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports12
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

11 rowsOpen in the library →
StudyTypeYearSummary depth
Dengzhanxixin injection for acute ischemic stroke after reperfusion therapy: A double-blind, placebo-controlled, multi-center clinical trial.
Finding78.21% with mRS 0-1 at 90 days in high-dose group
Human2026Full text read0.90
Robotic-assisted intracorporeal radical cystectomy with modified ileal conduit reduces ureteroileal anastomotic stenosis risk: a comparative study with laparoscopic surgery.
Finding0% stenosis in robotic group vs 15.22% in laparoscopic, p=0.043
Human2026Full text read0.80
Recommendations for quality care indicators in severe asthma multidisciplinary units in Portugal (PRECISION project): A nationwide consensus.
FindingConsensus achieved on 28/54 statements (51.9%).
review2026Full text read0.80
Development and diagnostic performance of a modified O-RADS model incorporating septa number and blood flow for adnexal lesions.
FindingMalignancy rate of 45.3% in the 4b subclass (86 masses), n=86.
Human2026Full text read0.80
Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial.
FindingAt 6 months, physical performance test improvement was greater in the intensive lifestyle plus metformin group than in the healthy lifestyle plus metformin group (mean difference 2·5 points, 95% CI 1·2-3·8; p=0·0002)
Human2026Full text read0.80
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
TakeawayInjectable peptides like CJC-1295 are still largely experimental, and clinicians should be cautious about their use due to uncertain efficacy and safety risks.
review2026Full text read0.80
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
TakeawayInjectable peptides for sports medicine are largely experimental and clinicians should be cautious about their efficacy and safety, particularly regarding products like CJC-1295.
review2026Full text read0.70
Semantic Scholar search for CJC-1295
TakeawayNot reported in abstract.
—2010Title only0.00
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
FindingLOD of 0.2 ng/mL.
review2023Partial text0.50
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
FindingNot reported in abstract.
—2024Partial text0.40
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
FindingAchieved LODs (≤ 0.5 ng/mL) and LOIs (0.5-0.75 ng/mL).
—2026Partial text0.60

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching CJC-1295 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much CJC-1295 is discussed should be drawn from it.

Articles mentioning CJC-1295